期刊文献+

阿立哌唑治疗难治性精神分裂症患者的疗效和安全性 被引量:19

Efficacy and safety of aripiprazole in treatment-resistant schizophrenia
下载PDF
导出
摘要 目的:探讨阿立哌唑治疗门诊难治性精神分裂症患者的疗效和安全性。方法:204例入组患者符合中国精神障碍分类与诊断标准第3版精神分裂症的诊断标准,且符合难治性精神分裂症的标准。所有患者接受为期8周的阿立哌唑开放性治疗,在基线、治疗2、4和8周采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:阿立哌唑治疗4周开始起效,治疗8周,有效率为55.4%。治疗4和8周,患者PANSS总分减分率有统计学意义(t=2.44,P<0.05;t=3.61,P<0.01),PANSS阳性分减分率有统计学意义(t=3.53,P<0.05;t=3.89,P<0.01),PANSS阴性分减分率有统计学意义(t=3.19,P<0.05;t=4.02,P<0.01)。主要不良反应为焦虑、头晕头痛、失眠、恶心呕吐、嗜睡等。结论:阿立哌唑对于难治性精神分裂症患者的治疗具有一定的疗效,不良反应少,耐受性较好。 Objective: To investigate the clinical efficacy and safety of aripiprazole in treatment-resistant schizophrenia(TRS) in outpatient service. Method:Two hundred and four outpatients who met schizophrenia criteria of Chinese Classification of Mental Disorders-3 and the TRS criteria were treated with single-dosage aripiprazole for 8 weeks. Efficacy and adverse events at baseline ,week 2,4 and 8 after the treatment were assessed by the positive and negative symptom scale (PANSS) and the treatment emergent symptom scale (TESS) , respectively. Results: PANSS total scores significantly decreased ( P 〈 0.05 ) since the end of 4th week treatment,and continued to decrease at the end of 8th week treatment. The responsive rate was 55.4%. The most common adverse events were anxiety, headache, insomnia, nausea, and drowsiness. Conclusion : These results suggest that aripiprazole is effective and relatively safe in treatment of patients with TRS.
出处 《临床精神医学杂志》 2012年第1期18-20,共3页 Journal of Clinical Psychiatry
关键词 难治性精神分裂症 阿立哌唑 refractory schizophrenia aripiprazole
  • 相关文献

参考文献15

  • 1姜小琴,杨开仁,周波,金庞,郑利峰,高晓峰,钱秀莲,余利霞.利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究[J].中国神经精神疾病杂志,2009,35(2):79-83. 被引量:26
  • 2Kane J. Treatment resistant schizophrenic patient [ J ]. J Clin Psy- chiatry, 1996,57 ( Suppl 9) :35-40.
  • 3Disayavanish C, Srisurapanont M, Udomratn P, et al. Guideline for the pharmacotherapy of treatment-resistant schizophrenia [ J ]. J Med Assoc Thai ,2000,83:579-589.
  • 4Taylor DM, Duncan-McConnell D. Refractory sehizophrenia and a- typical antipsychotics [ J ]. J Psychopharmaco1,2000,14:409-418.
  • 5Carpenter WT, Buchanan RW. Lessons to take home from CATIE [ J ]. Psychiatr Serv,2008 ,59 :523-525.
  • 6Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozap- ine in treatment-resistant or treatment-intolerant schizophrenia [ J ]. Prog Neuropsychopharmacol Biol Psychiatry. 2004,28:173-180.
  • 7汪志良,金卫东.难治性精神分裂症概念、类型及其治疗策略的认识[J].中国神经精神疾病杂志,2005,31(5). 被引量:39
  • 8Ziegenbein M, Sieberer M, Calliess IT, et al. Combination of cloza- pine and aripiprazole: a promising approach in treatment-resistant schizophrenia [ J ]. AustN Z J Psychiatry, 2005,39 : 840 -841.
  • 9Kane JM, Carson WH, Kujawa MJ, et al. Aripiprazole versus per- phenazine in treatment-resistant schizophrenia [ C ]. Poster presen- ted at 156th Annual Meeting of the American Psychiatric Associa- tion ;2003 : 17-22.
  • 10王立钢,王东明,孙艳.阿立哌唑与氟哌啶醇治疗难治性精神分裂症的对照研究[J].神经疾病与精神卫生,2006,6(1):38-39. 被引量:3

二级参考文献44

共引文献93

同被引文献130

引证文献19

二级引证文献187

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部